• 1
    Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 29948.
  • 2
    Van Der Giessen WJ, Zijlstra FJ, Berk L, Verdouw PD. The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig. Eur J Pharmacol 1988; 147: 2418.
  • 3
    Takiguchi Y, Wada K, Nakashima M. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats. possible role of TXA2. Thromb Haemost 1992; 68: 4603.
  • 4
    Kotze HF, Lamprecht S, Badenhorst PN, Van Wyk V, Roodt JP, Alexander K. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist. Thromb Haemost 1993; 70: 6725.
  • 5
    Krupinski K, Ferber H, Breddin HK, Bielawiec M. The antithrombotic effect of thromboxane receptor antagonist HN 11500 on thrombus formation in laser thrombosis model and platelet function tests. Acta Haematol Pol 1994; 25: 23542.
  • 6
    Shirakura S, Higo K, Takeda M, Karasawa A. Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol 1994; 65: 938.
  • 7
    Serruys PW, Rutsch W, Heyndrickx GR, Danchin N, Mast EG, Wijns W, Rensing BJ, Vos J, Stibbe J. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double- blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991; 84: 156880.
  • 8
    Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89: 58895.
  • 9
    Norris RM, White HD, Hart HH, Williams BF. Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression. N Z Med J 1996; 109: 27880.
  • 10
    Katsube N, Sakaguchi K, Fujitani B, Aishita H. Anti-platelet and anti-thrombotic effects of OP-41483 alpha-CD, a prostacyclin analogue, in experimental animals. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 795804.
  • 11
    Saito T, Saitoh S, Asakura T, Kanke M, Owada K, Maruyama Y. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model. Int J Cardiol 1993; 38: 22533.
  • 12
    Beitz A, Taube C, Beitz J, Goos H, Graff J, Nohring J, Lindenau KF, Mest HJ. Influence of iloprost on eicosanoid generation and lipid levels in experimental myocardial ischemia in dogs. Prostaglandins Leukot Essent Fatty Acids 1989; 35: 1415.
  • 13
    Kanayama T, Kimura Y, Tamao Y, Mizogami S. Beneficial effects of a new prostacyclin analogue, KP-10614, on acute myocardial infarction in rats. J Cardiovasc Pharmacol 1992; 20: 6307.
  • 14
    Shima K, Umezawa H, Chigasaki H, Okuyama S, Araki H. Stable prostacyclin improves postischaemic microcirculatory changes in hypertensive rats. Acta Neurochir (Wien) 1995; 137: 8995.
  • 15
    Miyauchi Y. [Treatment of the peripheral vascular diseases with prostaglandin]. Nippon Rinsho 1994; 52: 21826.
  • 16
    Nagaya N, Uematsu M, Okano Y, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Miyatake K, Kunieda T. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 118892.
  • 17
    Parise LV, Venton DL, Le Breton GC. Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation. Thromb Res 1982; 28: 72130.
  • 18
    Sturzebecher S, Witt W. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation. Prostaglandins 1988; 36: 75160.
  • 19
    Bertele V, De Gaetano G. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Eur J Pharmacol 1982; 85: 3313.
  • 20
    Yamada N, Isogaya M, Ueno Y, Kumagai H, Ochi Y, Nishio S. Synergic effect of beraprost sodium, a PGI2 analogue, and aspirin on canine carotid artery thrombosis model induced by electrical stimulation. Thromb Haemost 1993; 69 (Suppl.): 591.
  • 21
    Ohno K, Nagase H, Matsumoto K, Nishiyama H, Nishio S. In: Advances in Prostaglandin Thromboxane and Leukotriene Research, Vol. 15. Hayashi, O, Yamamoto, S, eds. New York: Raven Press, 1985.
  • 22
    Hayashi K, Nagamatsu T, Oka T, Suzuki Y. Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2. Synthase Jpn J Pharmacol 1997; 73: 7382.
  • 23
    Houston DS, Shepherd JT, Vanhoutte PM. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. Role of serotonin, thromboxane A2, and adenine nucleotides. J Clin Invest 1986; 78: 53944.
  • 24
    Webb ML, Liu ECK, Monshizadegan H, Hedberg H, Misra RN, Goldenberg H, Harris DN. Binding and function of a poten new thromboxane receptor antagonist, BMS 180291, in human platelets. J Pharmacol Exp Ther 1993; 264: 138794.
  • 25
    Cheng YC, Prusoff WH. Relation between the inhibition constant (Ki) and the concentration of inhibitor which cause 50 percent inhibition of an enzyme reaction. Biochem Pharmacol 1973; 22: 3099109.
  • 26
    Hill AV. A new mathematical treatment of ionic concentration in muscle and nerve under the action of electric currents, with a theory as to their mode of excitation. J Physiol (Lond) 1910; 40: 109224.
  • 27
    Nogimori K, Kajikawa N, Nishio S, Yajima M. Effects of TRK-100, a stable prostacyclin analogue, on regulation of cyclic AMP metabolism in platelets. Prostaglandins 1989; 37: 20512.
  • 28
    Nishio S, Matsuura H, Kanai N, Fukatsu Y, Hirano T, Nishikawa N, Kameoka K, Umetsu T. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 1988; 47: 110.
  • 29
    Armstrong RA, Jones RL, MacDermet J, Wilson NH. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin. Br J Pharmacol 1986; 87: 54351.
  • 30
    Zahavi M, Zahavi J. Relative insensitivity of epinephrine induced platelet aggregation to prostacyclin. Thromb Res 1986; 44: 11924.